Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 1;124(7):1326-1334.
doi: 10.1002/cncr.31153. Epub 2018 Jan 16.

Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire?

Deaglan J McHugh  1 , James C Root  2   3   4 , Christian J Nelson  2   3 , Michael J Morris  1   5
Affiliations
Review

Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire?

Deaglan J McHugh et al. Cancer. .

Abstract

Androgen-deprivation therapy (ADT) remains the cornerstone of management for patients with metastatic prostate cancer. Although the toxicities of ADT are well established, there is increasing controversy surrounding the association between cognitive dysfunction and the receipt of ADT, with some evidence suggesting an increased risk of dementia. The authors conducted a literature search to identify pertinent clinical studies in this field. This general review outlines the key findings and discusses the relative strengths and weaknesses when drawing conclusions about the risk of cognitive dysfunction or dementia with ADT use. Cancer 2018;124:1326-34. © 2018 American Cancer Society.

Keywords: Alzheimer's dementia; androgen deprivation; cognitive dysfunction; dementia; prostate cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Formation of androgen receptor mRNA and its expression in higher order cognitive brain centers
See this image and copyright information in PMC

References

    1. Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wennberg DC. The rising prevalence of androgen deprivation among older American men since the advent of prostate specific antigen testing: a population based cohort study. BJU international. 2006;98(5):973–8. - PMC - PubMed
    1. Barrass B, Thurairaja R, Persad R. More should be done to prevent the harmful effects of long term androgen ablation therapy in prostate cancer. BJU international. 2004;93(9):1175–6. - PubMed
    1. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103(8):1615–24. - PubMed
    1. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. The New England journal of medicine. 2009;360(24):2516–27. - PubMed
    1. Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. The Lancet Oncology. 2016;17(6):747–56. - PubMed

Publication types

Substances